The literature cluster reflects a decisive shift away from a purely amyloid-centric framework toward a multi-systems view of Alzheimer's Disease (AD) pathogenesis. While Aβ plaques, tangles, and the classical Amyloid Cascade/Amyloid Hypothesis remain foundational diagnostic and mechanistic anchors, the amyloid hypothesis is increasingly described as reframed rather than dismissed—reinterpreted within adaptive, evolutionary, and network-level contexts. This is paralleled by growing attention to alternative or complementary pathophysiological drivers: energy failure and mitochondrial biogenesis defects (with mitophagy-ferroptosis interactions and agents like Urolithin A emerging as therapeutic targets), ion channel dysregulation and network hyperexcitability affecting deep cortical excitatory-inhibitory subcircuits, and disrupted ionic and copper homeostasis linked to cuproptosis. Together these mechanisms position AD as a disease of cellular resource failure and circuit-level instability, not merely protein aggregation.
A second major thread concerns neuroimmune and glial mechanisms, particularly the TREM2-APOE axis driving Disease-Associated Microglia phenotypes, innate immunity (microglia and NK cells), and neuroinflammatory biomarkers such as YKL-40. APOE genotype threads through both immune modulation and general disease susceptibility, reinforcing its status as a central convergence node linking genetic risk, microglial state, and inflammatory burden. This neuroimmune axis intersects with vascular and metabolic contributors—hypertension, white matter hyperintensities, arteriolosclerosis (assessed via MRI), and the broader metabolic-aging interface—suggesting that cerebrovascular and cardiometabolic dysfunction compound neurodegeneration through shared inflammatory and oxidative stress pathways.
Therapeutically, the cluster shows diversification beyond disease-modifying antibodies: multitarget small molecules and cholinesterase-based inhibitors (exemplified by ASS234, Contilisant, (S)-p-methoxytacripyrine), phosphodiesterase-inhibiting nutraceuticals modulating cyclic nucleotide signaling, antioxidants like resveratrol targeting amyloid plaque deposition, and small molecules disrupting liquid-liquid phase separation or targeting YKL-40 and mitochondria-ER contact sites. Lifestyle interventions (Mediterranean diet, exercise-induced mitochondrial biogenesis) and prevention strategies aimed at cognitively unimpaired and preclinical populations reflect a parallel move toward earlier, modifiable-risk-based intervention, informed by biomarkers (synaptic proteins, plasma adipokines) and stratified by APOE4 status.
Finally, the cluster foregrounds population and translational dimensions: sex- and gonadal-hormone-modified pathology, bioinformatics-driven cross-disease comparisons (e.g., atherosclerosis and AD shared gene expression), microRNA-driven apoptotic pathway dysregulation, and health-systems gaps such as stigma and absent national dementia strategies in low-resource settings like Nigeria. Collectively, this signals a trend toward integrative, mechanism-diverse, and equity-conscious AD research replacing single-pathway paradigms.